oa Genetic modifiers to the PLN L39X mutation in a patient with DCM and sustained ventricular tachycardia?

References

1. Grimm W, Maisch B. Sudden cardiac death in dilated cardiomyopathy – therapeutic options. Herz. 2002; 27:8:750–759.
   [Google Scholar]
2. Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. Journal of the American College of Cardiology. 1998; 31:1:186–194.
   [Google Scholar]
3. Yacoub MH. Decade in review–cardiomyopathies: Cardiomyopathy on the move. Nature reviews Cardiology. 2014; 11:11:628–629.
   [Google Scholar]
4. Shaw T, Elliott P, McKenna WJ. Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet. 2002; 360:9334:654–655.
   [Google Scholar]
5. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW, MacLennan DH, Kranias EG. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. The Journal of biological chemistry. 2001; 276:26:24145–24152.
   [Google Scholar]
6. Schmidt AG, Zhai J, Carr AN, Gerst MJ, Lorenz JN, Pollesello P, Annila A, Hoit BD, Kranias EG. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure. Cardiovascular research. 2002; 56:2:248–259.
   [Google Scholar]
7. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovascular research. 2004; 61:2:208–217.
   [Google Scholar]
8. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends in cardiovascular medicine. 2004; 14:2:61–66.
   [Google Scholar]
9. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW, MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. The Journal of clinical investigation. 2003; 111:6:869–876.
   [Google Scholar]
10. Arvanitis DA, Sanoudou D, Kolokathis F, Vafiadaki E, Papalouka V, Kontrogianni-Konstantopoulos A, Theodorakis GN, Paraskevaidis IA, Adamopoulos S, Dorn GW, Kremastinos DT, Kranias EG. The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy. European heart journal. 2008; 29:20:2514–2525.
    [Google Scholar]
11. Lopes LR, Syrris P, Guttmann OP, O'Mahony C, Tang HC, Dalageorgou C, Jenkins S, Hubank M, Monserrat L, McKenna WJ, Plagnol V, Elliott PM. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015; 101:4:294–301.
    [Google Scholar]
12. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. Journal of molecular and cellular cardiology. 2000; 32:12:2131–2139.
    [Google Scholar]
13. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nature reviews Molecular cell biology. 2003; 4:7:566–577.
    [Google Scholar]
14. Landstrom AP, Adekola BA, Bos JM, Ommen SR, Ackerman MJ. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. American heart journal. 2011; 161:1:165–171.
    [Google Scholar]
15. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I. Circulation. 2001; 104:17:2113–2116.
    [Google Scholar]
16. Osterziel KJ, Perrot A. Dilated cardiomyopathy: more genes means more phenotypes. European heart journal. 2005; 26:8:751–754.
    [Google Scholar]
17. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998; 98:21:2334–2351.
    [Google Scholar]
18. Bai Y, Jones PP, Guo J, Zhong X, Clark RB, Zhou Q, Wang R, Vallmitjana A, Benitez R, Hove-Madsen L, Semeniuk L, Guo A, Song LS, Duff HJ, Chen SR. Phospholamban knockout breaks arrhythmogenic Ca(2)(+) waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice. Circulation research. 2013; 113:5:517–526.
    [Google Scholar]
19. Foell JD, Balijepalli RC, Delisle BP, Yunker AM, Robia SL, Walker JW, McEnery MW, January CT, Kamp TJ. Molecular heterogeneity of calcium channel beta-subunits in canine and human heart: evidence for differential subcellular localization. Physiological genomics. 2004; 17:2:183–200.
    [Google Scholar]
20. Lao QZ, Kobrinsky E, Harry JB, Ravindran A, Soldatov NM. New Determinant for the CaVbeta2 subunit modulation of the CaV1.2 calcium channel. The Journal of biological chemistry. 2008; 283:23:15577–15588.
    [Google Scholar]
21. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP Jr, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haïssaguerre M, Schimpf R. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007; 115:4:442–449.
    [Google Scholar]
22. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpon E, Hu D, Desai M, Borggrefe M, Häissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laiño R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DD, Viskin S, Winters S, Wolpert C. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart rhythm: the official journal of the Heart Rhythm Society. 2010; 7:12:1872–1882.
    [Google Scholar]
23. Molina-Navarro MM, Rosello-Lleti E, Ortega A, Tarazon E, Otero M, Martinez-Dolz L, Lago F, González-Juanatey JR, España F, García-Pavía P, Montero JA, Portolés M, Rivera M. Differential gene expression of cardiac ion channels in human dilated cardiomyopathy. PloS one. 2013; 8:12:e79792.
    [Google Scholar]
24. Brandmayr J, Poomvanicha M, Domes K, Ding J, Blaich A, Wegener JW, Moosmang S, Hofmann F. Deletion of the C-terminal phosphorylation sites in the cardiac beta-subunit does not affect the basic beta-adrenergic response of the heart and the Ca(v)1.2 channel. The Journal of biological chemistry. 2012; 287:27:22584–22592.
    [Google Scholar]
25. Opatowsky Y, Chen CC, Campbell KP, Hirsch JA. Structural analysis of the voltage-dependent calcium channel beta subunit functional core and its complex with the alpha 1 interaction domain. Neuron. 2004; 42:3:387–399.
    [Google Scholar]
26. Carboni N, Marrosu G, Porcu M, Mateddu A, Solla E, Cocco E, Maioli MA, Oppo V, Piras R, Marrosu MG. Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin-alpha2-chain gene: a chance association or a novel phenotype? Muscle & nerve. 2011; 44:5:826–828.
    [Google Scholar]
27. Hohenester E, Tisi D, Talts JF, Timpl R. The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin. Molecular cell. 1999; 4:5:783–792.
    [Google Scholar]
28. Marshall JD, Hinman EG, Collin GB, Beck S, Cerqueira R, Maffei P, Milan G, Zhang W, Wilson DI, Hearn T, Tavares P, Vettor R, Veronese C, Martin M, So WV, Nishina PM, Naggert JK. Spectrum of ALMS1 variants and evaluation of genotype-phenotype correlations in Alstrom syndrome. Human mutation. 2007; 28:11:1114–1123.
    [Google Scholar]
29. Czosek RJ, Goldenberg P, Miller EM, Spicer R, Towbin JA, Ware SM. Cardiac electrical system involvement in Alström syndrome: uncommon causes of dilated cardiomyopathies. Cardiogenetics. 2012; 2:e2:6–10.
    [Google Scholar]
30. Li G, Vega R, Nelms K, Gekakis N, Goodnow C, McNamara P, Wu H, Hong NA, Glynne R. A role for Alstrom syndrome protein, alms1, in kidney ciliogenesis and cellular quiescence. PLoS genetics. 2007; 3:1:e8.
    [Google Scholar]